261 related articles for article (PubMed ID: 30138689)
1. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.
Fontana RJ; Cirulli ET; Gu J; Kleiner D; Ostrov D; Phillips E; Schutte R; Barnhart H; Chalasani N; Watkins PB; Hoofnagle JH
J Hepatol; 2018 Dec; 69(6):1317-1325. PubMed ID: 30138689
[TBL] [Abstract][Full Text] [Related]
2. Terbinafine-associated hepatic injury.
van 't Wout JW; Herrmann WA; de Vries RA; Stricker BH
J Hepatol; 1994 Jul; 21(1):115-7. PubMed ID: 7963410
[TBL] [Abstract][Full Text] [Related]
3. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.
Nicoletti P; Aithal GP; Bjornsson ES; Andrade RJ; Sawle A; Arrese M; Barnhart HX; Bondon-Guitton E; Hayashi PH; Bessone F; Carvajal A; Cascorbi I; Cirulli ET; Chalasani N; Conforti A; Coulthard SA; Daly MJ; Day CP; Dillon JF; Fontana RJ; Grove JI; Hallberg P; Hernández N; Ibáñez L; Kullak-Ublick GA; Laitinen T; Larrey D; Lucena MI; Maitland-van der Zee AH; Martin JH; Molokhia M; Pirmohamed M; Powell EE; Qin S; Serrano J; Stephens C; Stolz A; Wadelius M; Watkins PB; Floratos A; Shen Y; Nelson MR; Urban TJ; Daly AK;
Gastroenterology; 2017 Apr; 152(5):1078-1089. PubMed ID: 28043905
[TBL] [Abstract][Full Text] [Related]
4. A Case of Progressive Cholestatic Drug-Induced Liver Injury Due to Terbinafine.
Ley D; Musto J; Said A
WMJ; 2023 May; 122(2):138-142. PubMed ID: 37141482
[TBL] [Abstract][Full Text] [Related]
5. Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor.
Urban TJ; Nicoletti P; Chalasani N; Serrano J; Stolz A; Daly AK; Aithal GP; Dillon J; Navarro V; Odin J; Barnhart H; Ostrov D; Long N; Cirulli ET; Watkins PB; Fontana RJ; ; ;
J Hepatol; 2017 Jul; 67(1):137-144. PubMed ID: 28323125
[TBL] [Abstract][Full Text] [Related]
6. Terbinafine-associated hepatotoxicity.
Ajit C; Suvannasankha A; Zaeri N; Munoz SJ
Am J Med Sci; 2003 May; 325(5):292-5. PubMed ID: 12792250
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles.
Fontana RJ; Li YJ; Phillips E; Saeed N; Barnhart H; Kleiner D; Hoofnagle J;
Liver Int; 2021 Aug; 41(8):1884-1893. PubMed ID: 33899326
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced cholestasis.
Bjornsson ES; Jonasson JG
Clin Liver Dis; 2013 May; 17(2):191-209. PubMed ID: 23540497
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histologic features of Azathioprine-induced hepatotoxicity.
Siramolpiwat S; Sakonlaya D
Scand J Gastroenterol; 2017 Aug; 52(8):876-880. PubMed ID: 28388864
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of laboratory abnormalities in patients prescribed terbinafine for onychomycosis.
Wang Y; Geizhals S; Lipner SR
J Am Acad Dermatol; 2021 Feb; 84(2):497-499. PubMed ID: 32387655
[No Abstract] [Full Text] [Related]
11. Azathioprine and 6-Mercaptopurine-induced Liver Injury: Clinical Features and Outcomes.
Björnsson ES; Gu J; Kleiner DE; Chalasani N; Hayashi PH; Hoofnagle JH;
J Clin Gastroenterol; 2017 Jan; 51(1):63-69. PubMed ID: 27648552
[TBL] [Abstract][Full Text] [Related]
12. Terbinafine-induced hepatotoxicity.
Mejías Manzano MLÁ; Giráldez Gallego Á; Ontanilla Clavijo G; Sousa Martín JM
Gastroenterol Hepatol; 2019; 42(6):394-395. PubMed ID: 31167724
[No Abstract] [Full Text] [Related]
13. Terbinafine-induced liver injury.
Kaushal M; Tolani P; Kumar N; Sharma S
Natl Med J India; 2017; 30(6):321-323. PubMed ID: 30117442
[TBL] [Abstract][Full Text] [Related]
14. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.
Fontana RJ; Hayashi PH; Barnhart H; Kleiner DE; Reddy KR; Chalasani N; Lee WM; Stolz A; Phillips T; Serrano J; Watkins PB;
Am J Gastroenterol; 2015 Oct; 110(10):1450-9. PubMed ID: 26346867
[TBL] [Abstract][Full Text] [Related]
15. [Hepatotoxicity associated with the use of Herbalife].
Jóhannsson M; Ormarsdóttir S; Olafsson S
Laeknabladid; 2010 Mar; 96(3):167-72. PubMed ID: 20197595
[TBL] [Abstract][Full Text] [Related]
16. Clinical and histopathologic features of fluoroquinolone-induced liver injury.
Orman ES; Conjeevaram HS; Vuppalanchi R; Freston JW; Rochon J; Kleiner DE; Hayashi PH;
Clin Gastroenterol Hepatol; 2011 Jun; 9(6):517-523.e3. PubMed ID: 21356330
[TBL] [Abstract][Full Text] [Related]
17. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients.
Li X; Jin S; Fan Y; Fan X; Tang Z; Cai W; Yang J; Xiang X
Biomed Pharmacother; 2019 Sep; 117():109095. PubMed ID: 31202168
[TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of Fenofibrate-Induced Liver Injury.
Ahmad J; Odin JA; Hayashi PH; Chalasani N; Fontana RJ; Barnhart H; Cirulli ET; Kleiner DE; Hoofnagle JH
Dig Dis Sci; 2017 Dec; 62(12):3596-3604. PubMed ID: 29119413
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature.
Gupta AK; del Rosso JQ; Lynde CW; Brown GH; Shear NH
Clin Exp Dermatol; 1998 Mar; 23(2):64-7. PubMed ID: 9692307
[TBL] [Abstract][Full Text] [Related]
20. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection.
Paredes AH; Lewis JH
Ann Pharmacother; 2007 May; 41(5):880-4. PubMed ID: 17426078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
